panitumumab

High Alert

Wild-type RAS (wild type in KRAS and NRAS) metastatic colorectal cancer that has failed fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy (as monotherapy).
Wild-type RAS (wild type in KRAS and NRAS) metastatic colorectal cancer (as first-line therapy with FOLFOX).
KRAS G12C-mutated metastatic colorectal cancer in patients who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (in combination with sotorasib).

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Concurrent use of leucovorin;
RAS: mutant metastatic colorectal cancer or unknown RAS mutation status (↑ mortality and tumor progression);
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: edema

Derm: acneiform dermatitis, dry skin, erythema, paronychia, pruritus, rash, skin exfoliation, skin fissures, abscesses, NECROTIZING FASCIITIS, photosensitivity

EENT: corneal perforation, eyelash growth, keratitis, ulcerative keratitis

F and E: hypomagnesemia, hypocalcemia

GI: abdominal pain, constipation, diarrhea, nausea, vomiting, stomatitis

GU: acute renal failure

Neuro: fatigue

Resp: cough, INTERSTITIAL LUNG DISEASE (ILD), PULMONARY FIBROSIS

Misc: INFUSION REACTIONS

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection: 20 mg/mL

Route/Dosage ⬆ ⬇

RAS Wild-Type Metastatic Colorectal Cancer

IV (Adults ): 6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity.

KRAS G12C: Mutated Metastatic Colorectal Cancer

IV (Adults ): 6 mg/kg every 14 days; continue until disease progression, unacceptable toxicity, or until sotorasib is withheld or discontinued. Administer 1st sotorasib dose before 1st panitumumab infusion.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Binds to epidermal growth factor receptor, resulting in inactivation of kinases that regulate proliferation and transformation.

Therapeutic effects:

Decreased progression of colorectal cancer.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 7.5 days.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	unknown	end of infusion	unknown

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of panitumumab. If an appointment is missed, reschedule as soon as possible. Advise patient to read Patient Information before starting and with each Rx refill in case of changes.
Emphasize the importance of regular follow-ups and eye exams to monitor for side effects and periodic blood tests to monitor electrolyte levels.
May cause photosensitivity. Caution patient to wear sunscreen and hats and to limit sun exposure. Advise patient to avoid tanning beds during treatment and for 2 mo following therapy, as sunlight may ↑ risk of dermatologic reactions.
Instruct patient to report symptoms of hypomagnesemia, hypocalcemia, or hypokalemia (muscle twitches, spasms, weakness, or cramps; heart palpitations).
Advise patient to notify health care provider if signs and symptoms of dermatologic toxicity, infusion reactions, pulmonary fibrosis, or ocular changes occur.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications.
Rep: May cause fetal harm. Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Advise women of reproductive potential to use effective contraception and to avoid breastfeeding during therapy and for 2 mo after last dose. May impair fertility in women.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

55513- Amgen Inc
- 55513-954- Vectibix
  - 55513-954-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-954-01) / 5 mL in 1 VIAL, SINGLE-DOSE

55513- Amgen Inc
- 55513-954- Vectibix
  - 55513-954-21- 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-954-21) / 5 mL in 1 VIAL, SINGLE-DOSE

55513- Amgen Inc
- 55513-956- Vectibix
  - 55513-956-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-956-01) / 20 mL in 1 VIAL, SINGLE-DOSE

55513- Amgen Inc
- 55513-956- Vectibix
  - 55513-956-21- 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-956-21) / 20 mL in 1 VIAL, SINGLE-DOSE

section name header

Indications ⬇